Metraipolis › archive › dc_bf5a418ac096

Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives — Europe PMC PMID:41893758

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41893758
DOI
10.3390/vaccines14030221
License (as archived)
solo-consultazione
Archived
2026-11-05T12:45:16.357Z
SHA-256 of the archived text
cc11eaa40c141cd8a7bfe1f1317c32b8e4e7a02f9b243f273405dfb4fcc90535
Stable URL of this page
https://metraipolis.com/documento/dc_bf5a418ac096

How to cite

Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives — Europe PMC PMID:41893758 — Europe PMC (en), https://europepmc.org/article/MED/41893758 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bf5a418ac096 (Metraipolis archive dc_bf5a418ac096, sha256 cc11eaa40c141cd8a7bfe1f1317c32b8e4e7a02f9b243f273405dfb4fcc90535)
BibTeX
@misc{dcbf5a418ac096,
  title = {Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives — Europe PMC PMID:41893758},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41893758},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bf5a418ac096; sha256 cc11eaa40c141cd8a7bfe1f1317c32b8e4e7a02f9b243f273405dfb4fcc90535},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41893758. Agents can read the archived copy with the MCP tool read_document.